Based on these results and the detected high mTOR activity in many cancers, mTOR inhibitor therapies have been tested in highly metastatic and aggressive cancer types characterized by high mTOR activity (e.g., pancreas, relapsed HER2 + , and TN breast cancers, EGFRI-resistant or cisplatin-, radiotherapy-resistant cancers). This evidence concerns the gene ERBB2 and cancer.